Results 131 to 140 of about 2,071 (176)

Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis). [PDF]

J Clin Med
Burlando M, Sacchelli L, Bettacchi A, Brunasso Vernetti GA, Caccavale S, Balato A, Cagni AE, Chersi K, Conti A, Costanzo A, D'amico D, De Simone C, Di Lernia V, Esposito M, Giofre' C, Gisondi P, Graziola F, Lembo S, Licciardello M, Loconsole F, Malagoli P, Satolli F, Susi ME, Strippoli D, Cozzani EC.   +24 more
europepmc   +1 more source

Case Report: Switching secukinumab to bimekizumab in diffuse cutaneous systemic sclerosis after autologous hematopoietic stem cell transplantation: a case follow-up. [PDF]

Front Immunol
Nagler LK, Strunz PP, Labinsky H, Kroiß A, Gernert M, Schmalzing M.   +5 more
europepmc   +1 more source

Interleukin-17 in disease pathogenesis and therapy: recent advances in targeted drug design and medicinal chemistry. [PDF]

Front Pharmacol
Wen J, Liu F, Zhang L, Lu L, Liang S, Du S.   +5 more
europepmc   +1 more source

Comparison of the Effects and Safety of Planned Limited-Time Withdrawal Versus Continuous Maintenance of Interleukin Inhibitors in Patients with Psoriasis: A Systematic Review and Network Meta-Analysis. [PDF]

Dermatol Ther (Heidelb)
de Sena RR, de C Mesquita K, Barroso LF, Canabrava PBE, Zanghelini F, Gomes CM.   +5 more
europepmc   +1 more source

A Retrospective Review of Real-World Patterns of Biologic Use in Dermatology Across Metropolitan, Regional and Rural Settings. [PDF]

Australas J Dermatol
Abeysekera N, Sibanda K, Park C, Griffin J, Wagner G, Banney L.   +5 more
europepmc   +1 more source

Bimekizumab for Psoriasis: Raising the Bar in Treatment

International Journal of Dermatology
openaire   +2 more sources

Bimekizumab for the treatment of psoriatic disease

Expert Opinion on Biological Therapy, 2018
Psoriasis and psoriatic arthritis are common diseases with significant physical and emotional burden. Several biologics are FDA-approved to treat psoriasis and psoriatic arthritis, though some patients remain refractory to, or have lost response to, therapy and/or cannot tolerate the associated risks and side effects. Bimekizumab is a new biologic that
Alice Gottlieb, Nicola Natsis
exaly   +4 more sources

Bimekizumab

Current Dermatology Reports, 2020
Purpose of Review: Bimekizumab, a novel monoclonal antibody directed against both interleukin (IL)-17A and IL-17F, is in clinical development as a treatment for psoriasis and psoriatic arthritis. The purpose of this review is to highlight the roles of IL-17A and IL-17F in psoriatic inflammation as well as the clinical data on bimekizumab that has been ...
Blauvelt A., Chiricozzi A., Ehst B. D.
openaire   +2 more sources